Geburtshilfe Frauenheilkd 2020; 80(10): e191
DOI: 10.1055/s-0040-1718141
Poster
Mittwoch, 7.10.2020
Gynäkologische Onkologie I

CIN2+ diagnoses between 2013 and 2018 in women 18 to 45 years old – Results from a German statutory health insurance claims data analysis

Authors

  • M Hampl

    1   Department of Obstetrics and Gynecology, University of Düsseldorf, Düsseldorf, Deutschland

  • A.-J Stephan

    2   MSD Sharp & Dohme GmbH, Market Access, Haar, Deutschland

  • R Wölle

    2   MSD Sharp & Dohme GmbH, Market Access, Haar, Deutschland

  • V.S Prabhu

    3   Merck & Co., Inc., Center for Observational and Real-World Evidence (CORE), Kenilworth, Vereinigte Staaten von Amerika

  • S Tanniru

    3   Merck & Co., Inc., Center for Observational and Real-World Evidence (CORE), Kenilworth, Vereinigte Staaten von Amerika

  • C Jacob

    4   Xcenda GmbH, Real World Evidence, Hannover, Deutschland

  • K.M Schneider

    4   Xcenda GmbH, Real World Evidence, Hannover, Deutschland

  • A Schneider

    4   Xcenda GmbH, Real World Evidence, Hannover, Deutschland

  • W Greiner

    5   Department of Health Economics and Health Care Management, Bielefeld University, School of Public Health, Bielefeld, Deutschland

  • M Reuschenbach

    6   MSD Sharp & Dohme GmbH, Medical Affairs, Haar, Deutschland
Further Information
Also available at
 
 

Objectives Cervical intraepithelial neoplasia (CIN) can result from Human Papillomavirus (HPV) infection, can present considerable burden to patients (surgical procedures/psychosocial consequences) and may be prevented by HPV vaccination. The objective was to estimate the 2013-2018 annual proportion of women 18-45 years-old with CIN2+ diagnoses in Germany.

Methods We conducted a retrospective cross-sectional claims data analysis using the Institute for Applied Health Research Berlin (InGef) Database, representative of the German population regarding age and gender. The annual proportion (2013-2018) of 18-45 year-olds with CIN2+ diagnoses was calculated as number of women with at least one respective ICD-10-GM record divided by the total number of women in the database.

Results The overall proportion of women 18-45 years-old with CIN2+ diagnoses was 7.9/1,000, 8.2/1,000, 7.7/1,000, 7.2/1,000, 7.0/1,000, and 6.7/1,000 in 2013, 2014, 2015, 2016, 2017, and 2018, respectively. Women 31-35 years-old accounted for 23.2 % and 28.3 % of CIN2+ diagnoses in 2013 and 2018, respectively. The proportion of 20-26-year-old women with CIN2+ diagnoses was 6.3/1,000 and 3.4/1,000 in 2013 and 2018, respectively (Figure 1).

Conclusions The burden of CIN2+ diagnosis in women >30 years remains substantial. Changes in CIN2+ diagnoses 2013-2018 could be driven by changes in HPV vaccination, behavior, and screening patterns.

Zoom
Annual proportion of women with CIN2+ diagnosis by age groups in Germany from 2013-2018.

Interessenkonflikt

This study was funded by MSD Sharp & Dohme GmbH. Anna-Janina Stephan, Miriam Reuschenbach, and Regine Wölle are full time employees of MSD Sharp & Dohme GmbH. Vimalanand S. Prabhu is a full-time employee and Sushama Tanniru is a full-time contractor of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Kim Maren Schneider, Alice Schneider, and Christian Jacob are full-time employees of Xcenda GmbH, acting as contractors of MSD Sharp & Dohme GmbH for the execution of this study. Wolfgang Greiner declares no conflict of interest. Monika Hampl received honoraria as speaker and member of medical advisory boards from MSD Sharp & Dohme GmbH.

Publication History

Article published online:
07 October 2020

© 2020. Thieme. All rights reserved.
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
Zoom
Annual proportion of women with CIN2+ diagnosis by age groups in Germany from 2013-2018.